NEW HAVEN, Conn., Oct. 23, 2018 (GLOBE NEWSWIRE) -- Arvinas Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on protein degradation, today announced it will be presenting at two upcoming conferences focused on protein degradation. The first is the Targeted Protein Degradation Conference, held October 23-25 at the Seaport Hotel and Trade Center, Boston. The second is the Protein Degradation Therapeutics Summit, held November 14th at the Battery Wharf Hotel in Boston.
Targeted Protein Degradation Conference
- Title: Keynote: PROTAC-mediated Protein Degradation: A New Therapeutic Modality
- Presenter: Dr. Craig Crews, Lewis B. Cullman Professor of MCDB; Prof. of Chemistry, Prof. of Pharmacology, Yale University and Founder and Chief Scientific Advisor of Arvinas
- Date and Time: October 23, 2018 – 9:00 AM
- Location: Seaport Hotel and Trade Center, Boston
- Case Study: Protein Degradation Approaches at Arvinas
- Presenter: Dr. Ian Taylor, SVP, Biology at Arvinas
- Date and Time: October 25, 2018 – 9:00 AM
- Location: Seaport Hotel and Trade Center, Boston
Protein Degradation Therapeutics Summit
- Title: Closing Panel and Open Q&A: What Needs to Happen Next for Protein Degradation Therapeutics R&D?
- Panelist: Dr. John Houston, President and CEO of Arvinas
- Date and Time: November 14, 2018 – 4:05 PM
- Location: Battery Wharf Hotel, Boston – Harborside Room
About Arvinas
Arvinas is a biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Arvinas uses its proprietary technology platform to engineer proteolysis targeting chimeras, or PROTAC™ protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins.
Contacts for Arvinas
Investor Relations
Randy Teel, VP Corporate Development
ir@arvinas.com
Media
Cory Tromblee, ScientPR
pr@arvinas.com